Results 121 to 130 of about 54,672 (154)
Some of the next articles are maybe not open access.
A safety update on sodium glucose co‐transporter 2 inhibitors
Diabetes, Obesity and Metabolism, 2019Sodium glucose co‐transporter 2 inhibitors (SGLT2is) are the first class of glucose lowering agent to be shown to reduce cardiovascular events. They are generally well tolerated with infrequent serious adverse events. The most frequent side effect is genital mycotic infections with candida species that are usually mild to moderate in severity, easily ...
openaire +2 more sources
Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes
Expert Opinion on Emerging Drugs, 2013Type 2 diabetes mellitus (T2DM) is a public health challenge globally. Numerous treatments are available which can improve insulin sensitivity or stimulate its secretion including biguanides, sulphonylureas and glitazones, as well as insulin, GLP-1 agonists and DPP-IV inhibitors.
Luke D, Boyle, John P H, Wilding
openaire +2 more sources
Caffeine intake enhances the benefits of sodium glucose transporter 2 inhibitor
Diabetes/Metabolism Research and Reviews, 2016AbstractBackgroundThe effect of sodium glucose transporter 2 (SGLT‐2) inhibitors is dependent on the glomerular filtration rate. It has been reported that caffeine intake increases glomerular filtration rate. However, the effect of caffeine intake on urinary glucose excretion in patients who take SGLT‐2 inhibitors is unclear.MethodsSix patients with ...
Yoshitaka Hashimoto +8 more
openaire +2 more sources
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Cell Metabolism, 2021Hiddo J L Heerspink, Taha Sen
exaly
Corticosteroids/sodium glucose transporter-2 inhibitors
Reactions Weekly, 2020openaire +1 more source